TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23648616

Group type: EXPERIMENTAL
Intervention: Covered viewing condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Uncovered viewing condition (dominant hand)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Uncovered viewing condition (non-dominant hand)
Number of subjects: 10
Study: 21059888

Group type: EXPERIMENTAL
Intervention: Apratastat (oral administration, single or multiple doses, twice daily)
Number of subjects: 3
Study: 19350334

Group type: EXPERIMENTAL
Intervention: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire completed twice a week for test-retest reliability (Group 1)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire with additional tests for validity (Group 2)
Number of subjects: 142
Study: 17237688

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled delivery system (Wand)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional manual syringe technique
Number of subjects: 30
Study: 15162250

Group type: EXPERIMENTAL
Intervention: Colour and power Doppler sonography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Presence of blood flow within the tendon
Number of subjects: 20
Study: 10693564

Group type: EXPERIMENTAL
Intervention: Tourniquet application (Group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No tourniquet application (Group II)
Number of subjects: 20
Study: 9408669

Group type: EXPERIMENTAL
Intervention: Specialist nurse intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no specialist nurse intervention)
Number of subjects: 45
Study: 7902637

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.04 mg.kg‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atracurium (0.2 mg.kg‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20
Study: 3026106

Group type: EXPERIMENTAL
Intervention: RIT 4237 vaccine alone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined administration of polio and RIT 4237 vaccines
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Poliovirus vaccine
Number of subjects: 160
Study: 31724083

Group type: EXPERIMENTAL
Intervention: Açai pulp (AP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 29482338

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis C-3102
Number of subjects: 0
Study: 27226338

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<130 mmHg or lower)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systolic blood pressure target (<140 mmHg)
Number of subjects: 0
Study: 24950747

Group type: EXPERIMENTAL
Intervention: GSK561679 (350 mg nightly for six weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching placebo for six weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK561679
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21885963

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18277183

Group type: EXPERIMENTAL
Intervention: Down syndrome participants (DS)
Number of subjects: 13
Study: 16182706

Group type: EXPERIMENTAL
Intervention: Celsior solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 50
Study: 12867606

Group type: EXPERIMENTAL
Intervention: Allergen-impermeable bed covers (active-intervention group)
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Non-impermeable bed covers (control group)
Number of subjects: 1122
Study: 10859040

Group type: EXPERIMENTAL
Intervention: Gavestinel (800 mg loading dose followed by 200 mg every 12 h for five doses)
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Gavestinel
Number of subjects: 1804
Study: 8817985

Group type: EXPERIMENTAL
Intervention: Nikkiso pump
Number of subjects: 20

Group type: COMPARATOR
Intervention: BioMedicus pump
Number of subjects: 20
Study: 1397742

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole, 40 mg i.v. bolus twice daily for up to 5 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Continuous infusion of ranitidine, 400 mg daily for the same time period
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole, 40 mg twice daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole, 40 mg three times daily
Number of subjects: 39
Study: 4010475

Group type: EXPERIMENTAL
Intervention: 14 gm choline and 0.35 mg scopolamine (Ch‐Sc)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo and scopolamine (Pl‐Sc)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo and placebo (Pl‐Pl)
Number of subjects: 10
Study: 30395147

Group type: EXPERIMENTAL
Intervention: Eating as Treatment (EAT)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Treatment as Usual (Control)
Number of subjects: 307
Study: 28682933

Group type: EXPERIMENTAL
Intervention: Capsaicin (12 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25758100

Group type: EXPERIMENTAL
Intervention: Type 1 implant placement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Type 2 implant placement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both Type 1 and Type 2 implant placements
Number of subjects: 38
Study: 24113508

Group type: EXPERIMENTAL
Intervention: Case-oriented self-learning and review
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (traditional lecture-based teaching)
Number of subjects: 185
Study: 22857850

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 2191

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 2191
Study: 20412501

Group type: COMPARATOR
Intervention: Fluoroscopically guided caudal epidural steroid, local anesthetic, and hypertonic saline (group 1)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fluoroscopically guided caudal epidural steroid, hypertonic saline, local anesthetic, and hyaluronidase (group 2)
Number of subjects: 38
Study: 18157412

Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (subcutaneous insulin)
Number of subjects: 24
Study: 15638906

Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1385
Study: 11331631

Group type: EXPERIMENTAL
Intervention: Immediate withdrawal of the catheter after embryo deposit (n = 51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 30 seconds delay before catheter withdrawal (n = 49)
Number of subjects: 100
Study: 9042093

Group type: EXPERIMENTAL
Intervention: Moderate beer consumption (330 mL/day, 20 g of alcohol) for 30 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no alcohol consumption)
Number of subjects: 28
Study: 7894522

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: BIA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: BIA in combination with waist-to-hip ratios
Number of subjects: 46
Study: 2468891

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 28
Study: 2318615

Group type: EXPERIMENTAL
Intervention: Health Diary I (HDI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Health Diary II (HDII)
Number of subjects: 76
Study: 1002750

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 30711247

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study: 27534402

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection followed by 12‐h infusion (IV‐IV)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intracoronary bolus injection followed by intravenous infusion (IC‐IV)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Only intracoronary bolus injection (IC)
Number of subjects: 99
Study: 27313412

Group type: COMPARATOR
Intervention: TC 150 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: TC 300 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: TC 150 mg and TC 300 mg
Number of subjects: 30
Study: 23972413

Group type: EXPERIMENTAL
Intervention: Guided self-instruction and additional CBT
Number of subjects: 169

Group type: COMPARATOR
Intervention: Waiting period followed by regular CBT
Number of subjects: 169
Study: 21289531

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T (Group 1)
Number of subjects: 715

Group type: COMPARATOR
Intervention: DTwP‐Hib, hepatitis B, and OPV vaccines (Group 2)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV‐Hep B‐PRP‐T with hepatitis B vaccine at birth (Group 3)
Number of subjects: 715
Study: 19814699

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg, once daily for 6 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg, once daily for 6 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17057415

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (subgroup of 6 volunteers)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15111618

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) with cyclophosphamide 1500 mg/m(2), thiotepa 150 mg/m(2), and mitoxantrone 10 mg/m(2) for 4 consecutive days followed by stem-cell support
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SD-CT) with cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) in three cycles
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SD-CT)
Number of subjects: 307
Study: 11692096

Group type: EXPERIMENTAL
Intervention: R-albuterol (6.25-1600 microg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RS-albuterol (12.5-3200 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: S-albuterol (6.25-1600 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9204651

Group type: EXPERIMENTAL
Intervention: Intravenous clodronate (600 mg or 1500 mg in 500 mL of normal saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous clodronate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (500 mL of saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blinded choice of agent for pain improvement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Investigators' blinded selection
Number of subjects: 60
Study: 7966073

Group type: EXPERIMENTAL
Intervention: Weekly sessions of supervised group physical therapy for a period of 9 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Daily exercises at home
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rating scale utilities
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Standard gamble utilities
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Change in rating scale utilities
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Change in standard gamble utilities
Number of subjects: 59
Study: 3475309

Group type: EXPERIMENTAL
Intervention: Group I: professional mechanical tooth‐cleaning, tongue‐scraping, chlorhexidine treatment, and oral hygiene instructions concentrated on the approximal surfaces, treatment given four times with intervals of two days, followed by one single treatment every six months
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Group II: same oral hygiene instructions as for Group I, repeated every six months
Number of subjects: 187

Group type: COMPARATOR
Intervention: Group III: preventive program by local Dental Health Office, based on mechanical plaque control and topical use of fluorides and chlorhexidine
Number of subjects: 187
Study: 29660956

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (conventional training)
Number of subjects: 37
Study: 27098717

Group type: EXPERIMENTAL
Intervention: Rotary method
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 50
Study: 25641556

Group type: EXPERIMENTAL
Intervention: Concizumab (subcutaneous or intravenous administration)
Number of subjects: 52
Study: 24099368

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 20923485

Group type: EXPERIMENTAL
Intervention: Self-monitoring blood glucose (SMBG)-based intervention
Number of subjects: 161

Group type: COMPARATOR
Intervention: HbA1c-based control group
Number of subjects: 161
Study: 18487892

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tai Chi-inspired exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study: 16413229

Group type: EXPERIMENTAL
Intervention: Investigational treatment
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Skilled professional care
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Altruism
Number of subjects: 247
Study: 14616411

Group type: EXPERIMENTAL
Intervention: voriconazole + erythromycin (1 g twice daily on days 8-14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: voriconazole + azithromycin (500 mg once daily on days 12-14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: voriconazole + erythromycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: voriconazole + azithromycin
Number of subjects: 30
Study: 11414066

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor
Number of subjects: 40

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 40
Study: 8978338

Group type: EXPERIMENTAL
Intervention: Same day back-to-back colonoscopy
Number of subjects: 183
Study: 7955820

Group type: EXPERIMENTAL
Intervention: Simendan (doses: 2 mg, 5 mg, 10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simendan (5 mg and 10 mg doses)
Number of subjects: 8
Study: 3024863

Group type: EXPERIMENTAL
Intervention: 25 mg oral captopril after 1 week of diuretic therapy (50 mg/day furosemide)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg/day furosemide
Number of subjects: 10
Study: 31646707

Group type: EXPERIMENTAL
Intervention: Baseline plasma renin activity (PRA) levels
Number of subjects: 618
Study: 28279222

Group type: EXPERIMENTAL
Intervention: Generalised linear mixed modelling approach
Number of subjects: 3

Group type: COMPARATOR
Intervention: Common analysis methods for stepped wedge trials
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Generalised linear mixed model
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Stepped wedge design with three steps
Number of subjects: 3
Study: 26116237

Group type: EXPERIMENTAL
Intervention: Exercise groups made up of participants of a similar age and same gender
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groups with similar-aged mixed gender participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed-aged mixed gender participants (control arm)
Number of subjects: 0
Study: 23782471

Group type: EXPERIMENTAL
Intervention: Croí MyAction intervention group (n=27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control arm (n=27)
Number of subjects: 54
Study: 21689270

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 795
Study: 19846694

Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) in patients with symptom onset of <2 years
Number of subjects: 118

Group type: COMPARATOR
Intervention: Microfracture (MF) in patients with symptom onset of <2 years
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) in patients with symptom onset of <3 years
Number of subjects: 118

Group type: COMPARATOR
Intervention: Microfracture (MF) in patients with symptom onset of <3 years
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) with high gene profile scores (>=2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI) with low gene profile scores (<2)
Number of subjects: 118
Study: 16988064

Group type: EXPERIMENTAL
Intervention: eGFR-based outcomes
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: iGFR-based outcomes
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: eGFR and iGFR slopes
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 1094
Study: 12716240

Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated from 25 mg/day to 100 mg/day for 6 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11055559

Group type: EXPERIMENTAL
Intervention: Capsaicin (2 mg x kg(‐1) ingested 1 hour prior to heat exposure)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (ingested 1 hour prior to heat exposure)
Number of subjects: 7
Study: 8612382

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate tablet coingested with cimetidine (300 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate solution coingested with cimetidine (300 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate tablet coingested with famotidine (40 mg)
Number of subjects: 2
Study: 1427946

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3882812

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 100
Study: 31282955

Group type: EXPERIMENTAL
Intervention: Caregiver depression (9-item Patient Health Questionnaire score of ≥10)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Caregiver burden
Number of subjects: 663

Group type: COMPARATOR
Intervention: Caregiver self-efficacy
Number of subjects: 663
Study: 30600667

Group type: EXPERIMENTAL
Intervention: Arthroscopic cystectomy combined with internal drainage (trial group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Arthroscopic internal drainage (control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (trial and control)
Number of subjects: 56
Study: 27649614

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (applied and re-applied up to 12 months)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Sealant (applied and re-applied up to 12 months)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ozone (applied and re-applied up to 12 months)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 107
Study: 24604360

Group type: EXPERIMENTAL
Intervention: Urea 10% applied to the oral cavity 3-4 times per day for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water)
Number of subjects: 38
Study: 21755401

Group type: EXPERIMENTAL
Intervention: Bone marker results at baseline, 3 and 12 months
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Educational materials every month and a membership in the National Osteoporosis Foundation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bone marker and educational information
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control, no information other than usual care
Number of subjects: 240
Study: 21152005

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Folate pathway model
Number of subjects: 194
Study: 17333135

Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 14
Study: 15377650

Group type: EXPERIMENTAL
Intervention: 60% O(2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 21% O(2)
Number of subjects: 10
Study: 12126242

Group type: EXPERIMENTAL
Intervention: Racecadotril (100 mg, three times daily)
Number of subjects: 945

Group type: COMPARATOR
Intervention: Loperamide (2 mg, three times daily)
Number of subjects: 945
Study: 9886591

Group type: EXPERIMENTAL
Intervention: Duloxetine (exact dosage and duration not specified)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 288
Study: 9226525

Group type: EXPERIMENTAL
Intervention: Formula with P:E ratio of 3.2 g/100 kcal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Formula with P:E ratio of 2.6 g/100 kcal
Number of subjects: 15
Study: 1778279

Group type: EXPERIMENTAL
Intervention: Proglumetacin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 2
Study: 7075196

Group type: EXPERIMENTAL
Intervention: Tapered Lippes Loop D (LLD)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Standard Lippes Loop D (LLD)
Number of subjects: 989
Study: 31917762

Group type: EXPERIMENTAL
Intervention: Gadopiclenol 0.2 mmol/kg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Gadopiclenol 0.1 mmol/kg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Gadopiclenol 0.05 mmol/kg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Gadopiclenol
Number of subjects: 272
Study: 30914268

Group type: EXPERIMENTAL
Intervention: MALDITOF-MS
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Conventional diagnostics
Number of subjects: 1005